Cargando…

Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-linked hypophosphatemia (XLH)

Mostrar otras versiones (1)

X-linked hypophosphatemia (XLH) is a rare disease of elevated fibroblast growth factor 23 (FGF23) production that leads to hypophosphatemia and impaired mineralization of bone and teeth. The clinical manifestations of XLH include a high prevalence of dental abscesses and periodontal disease, likely...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carpenter, Kelsey A., Alkhatib, Delia O., Dulion, Bryan A., Guirado, Elizabeth, Patel, Shreya, Chen, Yinghua, George, Anne, Ross, Ryan D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562382/ https://www.ncbi.nlm.nih.gov/pubmed/37813865 http://dx.doi.org/10.1038/s41368-023-00252-1

Ejemplares similares

Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-Linked Hypophosphatemia (XLH)
por: Ross, Ryan, et al.
Publicado: (2023)

X-linked Hypophosphatemia (XLH) Mimicking Rheumatic Disease
por: Takase, Ryosuke, et al.
Publicado: (2020)

Impaired 1,25 dihydroxyvitamin D(3) action and hypophosphatemia underlie the altered lacuno-canalicular remodeling observed in the Hyp mouse model of XLH
por: Yuan, Ye, et al.
Publicado: (2021)

Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children
por: Schindeler, Aaron, et al.
Publicado: (2020)

Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy
por: Brener, Avivit, et al.
Publicado: (2021)

Potential influences on optimizing long-term musculoskeletal health in children and adolescents with X-linked hypophosphatemia (XLH)
por: Glorieux, Francis H., et al.
Publicado: (2022)

Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy
por: Brener, Rafi, et al.
Publicado: (2022)

Novel PHEX gene locus‐specific database: Comprehensive characterization of vast number of variants associated with X‐linked hypophosphatemia (XLH)
por: Sarafrazi, Soodabeh, et al.
Publicado: (2021)

The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical data
por: Ariceta, Gema, et al.
Publicado: (2023)

Impaired 1,25-dihydroxyvitamin D(3) action underlies enthesopathy development in the Hyp mouse model of X-linked hypophosphatemia
por: Rana, Rakshya, et al.
Publicado: (2023)

SUN-363 Hypophosphatemia Gene Panel Sponsored Program: A High Yield Of Molecular Diagnoses from Clinically Confirmed XLH and Suspected XLH/ Genetic Hypophosphatemia
por: Miller, Nicole, et al.
Publicado: (2020)

Biomechanical Impact of Phosphate Wasting on Articular Cartilage Using the Murine Hyp Model of X‐linked hypophosphatemia
por: Macica, Carolyn M, et al.
Publicado: (2023)

OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH)
por: Imel, Erik, et al.
Publicado: (2019)

Persistent Lower Limb Deformities Despite Amelioration of Rickets in X-Linked Hypophosphatemia (XLH) - A Prospective Observational Study
por: Mindler, Gabriel T., et al.
Publicado: (2022)

SUN-356 Burosumab Resulted in Greater Clinical Improvements Compared with Higher-dose Conventional Therapy in Children with X-linked Hypophosphatemia (XLH)
por: Imel, Erik A, et al.
Publicado: (2020)

XLH Matters 2022: Insights and recommendations to improve outcomes for people living with X-linked hypophosphataemia (XLH)
por: Seefried, Lothar, et al.
Publicado: (2023)

Hypophosphatemia Gene Panel Sponsored Program: A High Yield of Molecular Diagnoses from Clinically Confirmed XLH and Suspected Genetic Hypophosphatemia
por: Dahir, Kathryn, et al.
Publicado: (2021)

Growth Curves for Children with X-linked Hypophosphatemia
por: Mao, Meng, et al.
Publicado: (2020)

OR13-3 Hypophosphatemia Gene Panel Sponsored Program: A High Yield of Molecular Diagnoses from Clinically Confirmed XLH and Suspected Genetic Hypophosphatemia
por: Japalaghi, Omid K, et al.
Publicado: (2022)

Wnt pathway inhibitors are upregulated in XLH dental pulp cells in response to odontogenic differentiation
por: Guirado, Elizabeth, et al.
Publicado: (2023)

Kbus/Idr, a mutant mouse strain with skeletal abnormalities and hypophosphatemia: Identification as an allele of 'Hyp'
por: Moriyama, Kenji, et al.
Publicado: (2011)

Serum Levels of Lipocalin Are Lower in Adolescents With X-Linked Hypophosphatemia
por: Simpson, Christine A, et al.
Publicado: (2021)

OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial
por: Perwad, Farzana, et al.
Publicado: (2020)

Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment
por: Kamenicky, Peter, et al.
Publicado: (2023)

Circulating Levels of Leptin and Lipocalin-2 in Patients With X-Linked Hypophosphatemia
por: Simpson, Christine A, et al.
Publicado: (2023)

Dental management of patients with X-linked hypophosphatemia
por: Lee, Bin-Na, et al.
Publicado: (2017)

Enthesopathy, Osteoarthritis, and Mobility in X-linked Hypophosphatemia
por: Imel, Erik A
Publicado: (2020)

Genotype and Phenotype Analysis in X-Linked Hypophosphatemia
por: Park, Peong Gang, et al.
Publicado: (2021)

Impact of X-Linked Hypophosphatemia on Muscle Symptoms
por: Romagnoli, Cecilia, et al.
Publicado: (2022)

Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia
por: Weber, Thomas J, et al.
Publicado: (2022)

Decreased Compressional Sound Velocity Is an Indicator for Compromised Bone Stiffness in X-Linked Hypophosphatemic Rickets (XLH)
por: Raimann, Adalbert, et al.
Publicado: (2020)

The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study
por: Padidela, Raja, et al.
Publicado: (2020)

Autism and X-linked hypophosphatemia: A possible association?
por: Joël, Vermeersch, et al.
Publicado: (2010)

SUN-526 Prevalence of Hyperparathyroidism in X-Linked Hypophosphatemia
por: DeLacey, Sean, et al.
Publicado: (2019)

X-Linked Hypophosphatemia: A New Era in Management
por: Dahir, Kathryn, et al.
Publicado: (2020)

Burosumab and Dental Abscesses in Children With X‐Linked Hypophosphatemia
por: Gadion, Margaux, et al.
Publicado: (2022)

Craniosynostosis in Patients With X‐Linked Hypophosphatemia: A Review
por: Munns, Craig F, et al.
Publicado: (2023)

A De Novo Deleterious PHEX Variant Without Clinical Features of X-Linked Hypophosphatemia
por: Kayser, Michelle, et al.
Publicado: (2023)

Increased prevalence of overweight and obesity in children with X-linked hypophosphatemia
por: Zhukouskaya, Volha V, et al.
Publicado: (2020)

Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish population
por: Rodríguez-Rubio, Enrique, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bataqe8u7gtu646u284v3ktuqh